Anfang April lud acib zum österreichischen Stakeholderevent aus dem Open Innovation Test-Bed (OITB) Projekt Bionanopolys ein. Acib ist Mitglied in diesem 27 Partner starken Projektkonsortium, das sich mit der Entwicklung von bio-basierten Nanomaterialen beschäftigt.

An intact microbiome protects our skin as a natural shield against external influences. However, if this sensitive system is disturbed, it can lead to serious skin diseases. A Styrian consortium has therefore set itself the goal of developing a natural, medical skin care product. Living bacteria contained in it are strengthening the skin microbiome and warding off pathogens.  

The pharmaceutical industry has had to resort to rather inefficient, environmentally harmful chemical synthesis routes for the production of the active ingredient levetiracetam, a drug which is used to treat epilepsy. A consortium led by acib has now developed a chemoenzymatic manufacturing route that promises twice the yield of current production methods while being environmentally friendly. The production method could be ready for industrial use in a year’s time.

Gut ein Jahr nach dem Ausbruch der Coronavirus-Pandemie ist sie den meisten Menschen ein Begriff: die Polymerase-Kettenreaktion, kurz PCR (englisch: polymerase chain reaction). Sie ist im Moment eines der verlässlichsten Werkzeuge, um eine Coronavirusinfektion nachzuweisen. Was passiert bei der PCR und warum ist sie soviel genauer als ein Antigentest?

Like any virus, SARS-CoV-2 is constantly changing. A wide variety of mutations are the result, to which vaccine manufacturers have so far only been able to react retroactively. Researchers from Graz, Austria have succeeded in using modern AI-based screening methods and virtual scenarios to study and predict the relevance of existing, but also future corona virus variants. This will allow vaccine manufacturers to optimize existing vaccines more quickly to make them effective against a wide range of mutations and to to gain earlier control over epidemics.

Researchers from TU Graz and acib succeed in the first enzyme-driven biocatalytic synthesis of nucleic acid building blocks. This facilitates the development of antiviral agents and RNA-based therapeutics.

Squalene acts as a booster for potential vaccines against SARS-CoV-2. However, the richest squalene source, shark liver, can and should not be exploited further. acib offers a solution: Yeast cell factories can be designed via biotechnological tools to produce high amounts of squalene.

Globally, the search for potential drugs and vaccines is proceeding rapidly. A collaborative acib-research project focuses on the identification, evaluation and pre-clinical testing of a certain group of active ingredients, combining faster availability with high effectiveness. These so-called antiviral drugs have been used in the fights against HIV, MERS and SARS. They can inhibit the multiplication rates of enzymes or prevent virus particles from invading lung cells and consequently avert  possible infections. This makes them effective tools in the fight against COVID-19.

Contactless magnetic heating may sound scary, but it is part of your daily life experience. Every time you heat-up your morning coffee mocha with an induction cooker, you are using magnetic fields and magnetic materials. But can this kind of heating also be used to solve high-tech problems? This is the question that scientists are trying to answer in the H2020-FETOPEN project HOTZYMES.

Whether activating or silencing genes, breaking down defective cells or building new tissue, our body is constantly working to repair itself, even in cases of illness. To fight a disease, our body sends out signals, often long before we ourselves notice the disease. Such signals are, for example, DNA molecules that are released from the body’s own cells, circulate in the blood and are most likely recognised by other cells as a message to stimulate a defence reaction. The identification of these messengers leads to an early detection of sepsis.